Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
2.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B.

Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

3.

Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid.

Wessels F, Kriegmair MC, Oehme A, Rassweiler-Seyfried MC, Erben P, Oberneder R, Kriegmair M, Ritter M, Michel MS, Honeck P.

Eur J Surg Oncol. 2019 Jul;45(7):1260-1265. doi: 10.1016/j.ejso.2019.02.023. Epub 2019 Feb 22.

PMID:
30827801
4.

Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.

von Hardenberg J, Hartmann S, Nitschke K, Worst TS, Ting S, Reis H, Nuhn P, Weis CA, Erben P.

Clin Genitourin Cancer. 2019 Apr;17(2):145-153.e5. doi: 10.1016/j.clgc.2018.12.007. Epub 2018 Dec 21.

PMID:
30709785
5.

Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5.

Nitschke K, Erben P, Waldbillig F, Abdelhadi A, Weis CA, Gottschalt M, Wahby S, Nuhn P, Boutros M, Michel MS, von Hardenberg J, Worst TS.

World J Urol. 2019 Jan 30. doi: 10.1007/s00345-019-02651-8. [Epub ahead of print]

PMID:
30701334
6.

Erratum to 'Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy' [Urologic Oncology: Seminars and Original Investigations 36/12 (2018) 505-534].

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P.

Urol Oncol. 2019 Mar;37(3):227. doi: 10.1016/j.urolonc.2018.12.019. Epub 2018 Dec 27. No abstract available.

PMID:
30595464
7.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
8.

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.

Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V.

Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 Nov 27.

PMID:
30483954
9.

Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy.

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P.

Urol Oncol. 2018 Dec;36(12):530.e19-530.e27. doi: 10.1016/j.urolonc.2018.09.003. Epub 2018 Nov 13. Erratum in: Urol Oncol. 2019 Mar;37(3):227.

PMID:
30446441
10.

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P.

Int J Mol Sci. 2018 Oct 30;19(11). pii: E3396. doi: 10.3390/ijms19113396.

11.

Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer.

von Hardenberg J, Worst TS, Westhoff N, Erben P, Fuxius S, Müller M, Bolenz C, Weiss C, Heinrich E.

Oncol Res Treat. 2018;41(10):627-633. doi: 10.1159/000490618. Epub 2018 Sep 10.

PMID:
30286478
12.

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P.

Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x.

13.

FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.

Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W.

BJU Int. 2019 Jan;123(1):187-196. doi: 10.1111/bju.14525. Epub 2018 Sep 9.

PMID:
30120861
14.

FOXM1 predicts disease progression in non-muscle invasive bladder cancer.

Rinaldetti S, Wirtz R, Worst TS, Hartmann A, Breyer J, Dyrskjot L, Erben P.

J Cancer Res Clin Oncol. 2018 Sep;144(9):1701-1709. doi: 10.1007/s00432-018-2694-5. Epub 2018 Jun 29.

15.

Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening.

Rinaldetti S, Rempel E, Worst TS, Eckstein M, Steidler A, Weiss CA, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 May 25;9(40):25935-25945. doi: 10.18632/oncotarget.25407. eCollection 2018 May 25.

16.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

17.

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany.

Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2.

PMID:
29525349
18.

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P.

Transl Oncol. 2018 Apr;11(2):467-476. doi: 10.1016/j.tranon.2018.02.001. Epub 2018 Feb 23.

19.

Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7.

Bolenz C, Knauf D, John A, Erben P, Steidler A, Schneider SW, Günes C, Gorzelanny C.

Bladder Cancer. 2018 Jan 20;4(1):67-75. doi: 10.3233/BLC-170124.

20.

High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.

Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A.

Cancer Immunol Immunother. 2018 Mar;67(3):403-412. doi: 10.1007/s00262-017-2093-9. Epub 2017 Nov 17.

PMID:
29150702
21.

Impact of Altered WNT2B Expression on Bladder Wall Fibroblasts: Implications for Apoptosis Regulation in the Stroma of the Lower Urinary Tract.

Worst TS, Daskalova K, Steidler A, Berner-Leischner K, Röth R, Niesler B, Kriegmair MC, Erben P, Pfalzgraf D.

Urol Int. 2017;99(4):476-483. doi: 10.1159/000481440. Epub 2017 Oct 31.

PMID:
29131138
22.

Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies.

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A.

Oncotarget. 2017 Jun 28;8(40):67684-67695. doi: 10.18632/oncotarget.18804. eCollection 2017 Sep 15.

23.

The EEF1A2 gene expression as risk predictor in localized prostate cancer.

Worst TS, Waldbillig F, Abdelhadi A, Weis CA, Gottschalt M, Steidler A, von Hardenberg J, Michel MS, Erben P.

BMC Urol. 2017 Sep 18;17(1):86. doi: 10.1186/s12894-017-0278-3.

24.

[Role of the human ErbB family receptors in urothelial carcinoma of the bladder: mRNA expression status and prognostic relevance].

Erben P, Wezel F, Wirtz R, Martini T, Stein D, Weis CA, Hartmann A, Bolenz C.

Aktuelle Urol. 2017 Aug;48(4):356-362. doi: 10.1055/s-0043-110403. Epub 2017 Jul 27. German.

PMID:
28750448
25.

Novel insights into a reputably irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy.

Worst TS, Daskalova K, Steidler A, Berner-Leischner K, Röth R, Niesler B, Weis CA, Kriegmair MC, Erben P, Pfalzgraf D.

World J Urol. 2017 Nov;35(11):1701-1711. doi: 10.1007/s00345-017-2060-2. Epub 2017 Jun 20.

PMID:
28634911
26.

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2017 Jul 18;8(29):47595-47606. doi: 10.18632/oncotarget.17394.

27.

Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.

Worst TS, von Hardenberg J, Gross JC, Erben P, Schnölzer M, Hausser I, Bugert P, Michel MS, Boutros M.

Mol Cell Proteomics. 2017 Jun;16(6):998-1008. doi: 10.1074/mcp.M117.068577. Epub 2017 Apr 9.

28.

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W.

Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22.

29.

RAB27A, RAB27B and VPS36 are downregulated in advanced prostate cancer and show functional relevance in prostate cancer cells.

Worst TS, Meyer Y, Gottschalt M, Weis CA, von Hardenberg J, Frank C, Steidler A, Michel MS, Erben P.

Int J Oncol. 2017 Mar;50(3):920-932. doi: 10.3892/ijo.2017.3872. Epub 2017 Feb 10.

PMID:
28197629
30.

In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.

Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Virchows Arch. 2017 Mar;470(3):267-274. doi: 10.1007/s00428-017-2064-8. Epub 2017 Jan 10.

PMID:
28074276
31.

ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.

Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A; BRIDGE Consortium.

Urol Int. 2017;98(3):282-289. doi: 10.1159/000453670. Epub 2016 Dec 17.

PMID:
27992871
32.

Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.

Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P.

Anticancer Res. 2016 Oct;36(10):5205-5213.

PMID:
27798881
33.

ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W.

Virchows Arch. 2016 Nov;469(5):547-552. Epub 2016 Aug 11.

PMID:
27514658
34.

Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal Cancer.

Kripp M, Merx K, Wirtz RM, Gaiser T, Eidt S, Schwaab J, Post S, Wenz F, Hochhaus A, Hofheinz RD, Erben P.

Gastroenterol Res Pract. 2016;2016:3481578. doi: 10.1155/2016/3481578. Epub 2016 Aug 16.

35.

Lapatinib-induced mesenchymal-epithelial transition in squamous cell carcinoma cells correlates with unexpected alteration of β-catenin expression.

Umbreit C, Erben P, Faber A, Hofheinz RD, Schultz JD, Hoermann K, Wenzel A.

Oncol Lett. 2016 Apr;11(4):2715-2724. Epub 2016 Mar 1.

36.

Low cytoplasmic and nuclear KPNA2 expression in radiotherapy-treated head and neck squamous cell cancer is associated with an adverse outcome.

Erben PB, Brunner K, Hecht M, Haderlein M, Büttner-Herold M, Agaimy A, Fietkau R, Hartmann A, Distel LV.

Int J Clin Exp Pathol. 2015 Dec 1;8(12):15814-24. eCollection 2015.

37.

Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine.

Wezel F, Erben P, Gaiser T, Budjan J, von Hardenberg J, Michel MS, Bolenz C.

Urol Int. 2018;100(1):122-125. doi: 10.1159/000443280. Epub 2016 Jan 19.

PMID:
26780095
38.

MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.

Umbreit C, Erben P, Faber A, Hofheinz RD, Aderhold C, Weiss C, Hoermann K, Wenzel A, Schultz JD.

Anticancer Res. 2015 Jul;35(7):3801-10.

PMID:
26124325
39.

[Molecular Characterisation of Urothelial Bladder Cancer: Will it Improve Patient Care?].

Erben P, Hartmann A, Bolenz C.

Aktuelle Urol. 2015 May;46(3):227-35. doi: 10.1055/s-0035-1549992. Epub 2015 Jun 12. Review. German.

PMID:
26077307
40.

Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with β-catenin expression.

Umbreit C, Flanjak J, Weiss C, Erben P, Aderhold C, Faber A, Stern-Straeter J, Hoermann K, Schultz JD.

Anticancer Res. 2014 Dec;34(12):7061-9.

PMID:
25503133
41.

[Detection of lymphovascular invasion in urothelial carcinoma of the bladder through D2-40 immunostaining].

Martini T, Ströbel P, Steidler A, Petrakopoulou N, Erben P, Bolenz C.

Urologe A. 2015 Jan;54(1):70-5. doi: 10.1007/s00120-014-3646-6. German.

PMID:
25391439
42.

IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking Status.

Worst TS, Reiner V, Gabriel U, Weiß C, Erben P, Martini T, Bolenz C.

Adv Urol. 2014;2014:184602. doi: 10.1155/2014/184602. Epub 2014 Jul 8.

43.

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.

Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius A, Schlegelberger B, Saußele S, Dietz CT, Erben P, Hehlmann R, Hasford J, Hochhaus A, Müller MC.

J Cancer Res Clin Oncol. 2014 Nov;140(11):1965-9. doi: 10.1007/s00432-014-1746-8. Epub 2014 Jun 22.

PMID:
24952896
44.

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Haematologica. 2014 Sep;99(9):1441-7. doi: 10.3324/haematol.2013.096537. Epub 2014 May 16.

45.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Leukemia. 2014 Oct;28(10):1988-92. doi: 10.1038/leu.2014.153. Epub 2014 May 6.

PMID:
24798484
46.

Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.

Gosenca D, Kellert B, Metzgeroth G, Haferlach C, Fabarius A, Schwaab J, Kneba M, Scheid C, Töpelt K, Erben P, Haferlach T, Cross NC, Hofmann WK, Seifarth W, Reiter A.

Genes Chromosomes Cancer. 2014 May;53(5):411-21.

PMID:
24772479
47.

Microvascular invasion of testicular nonseminomatous germ cell tumors: implications of separate evaluation of lymphatic and blood vessels.

Heinzelbecker J, Gross-Weege M, Weiss C, Hörner C, Trunk MJ, Erben P, Haecker A, Bolenz C.

J Urol. 2014 Aug;192(2):593-9. doi: 10.1016/j.juro.2014.02.2569. Epub 2014 Mar 12.

PMID:
24631105
48.

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.

Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Fabarius A, Saussele S, Purkayastha D, Woodman RC, Hofmann WK, Hehlmann R, Hochhaus A, Müller MC.

Leukemia. 2014 Jul;28(7):1478-85. doi: 10.1038/leu.2014.6. Epub 2014 Jan 10.

PMID:
24472814
49.

The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia.

Schmitt-Graeff AH, Erben P, Schwaab J, Vollmer-Kary B, Metzgeroth G, Sotlar K, Horny HP, Kreipe HH, Fisch P, Reiter A.

Blood. 2014 Jan 23;123(4):595-7. doi: 10.1182/blood-2013-10-530642. No abstract available.

50.

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).

Philipp M, Schwaab J, Dietz CT, Hanfstein B, Kalmanti L, Munjal U, Mossner M, Nowak D, Seifarth W, Hofmann WK, Hochhaus A, Müller MC, Erben P.

J Cancer Res Clin Oncol. 2014 Mar;140(3):411-7. doi: 10.1007/s00432-013-1579-x. Epub 2014 Jan 5.

PMID:
24390277

Supplemental Content

Support Center